Library.

“Living Cell Technologies conducted clinical trials in New Zealand in which islet cells from Auckland Island pigs were transplanted into eight patients with type 1 diabetes.”

The central claim is well supported: Living Cell Technologies did conduct New Zealand clinical studies using Auckland Island pig islet cells in patients with type 1 diabetes. The problem is the number. Eight patients matches an intermediate stage reported at the time, but the completed New Zealand trial later treated 14 patients, so the claim is accurate in substance but incomplete as stated.

“Individuals with Type 1 diabetes have nearly three times the risk of developing dementia compared to individuals without Type 1 diabetes.”

Type 1 diabetes is associated with elevated dementia risk, but "nearly three times" overstates the typical finding. The most comprehensive quantitative synthesis — a 2025 systematic review and meta-analysis — reports a pooled hazard ratio of approximately 1.50 (a 50% increase), while a large nationwide cohort study found roughly double the risk. The ~2.8× figure comes from one specific recent study and media reports echoing it, not from the broader evidence base. The claim cherry-picks the highest estimate rather than reflecting the range of peer-reviewed findings.